Roman Butler Fullerton & Co. Invests $473,000 in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Roman Butler Fullerton & Co. purchased a new stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) during the fourth quarter, HoldingsChannel.com reports. The institutional investor purchased 4,201 shares of the medical equipment provider’s stock, valued at approximately $473,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Asset Management One Co. Ltd. lifted its holdings in shares of Zimmer Biomet by 0.7% during the fourth quarter. Asset Management One Co. Ltd. now owns 81,913 shares of the medical equipment provider’s stock valued at $8,754,000 after purchasing an additional 602 shares in the last quarter. MFG Wealth Management Inc. bought a new position in shares of Zimmer Biomet during the fourth quarter valued at $1,506,000. Van ECK Associates Corp lifted its holdings in shares of Zimmer Biomet by 5.9% during the fourth quarter. Van ECK Associates Corp now owns 3,955,449 shares of the medical equipment provider’s stock valued at $417,814,000 after purchasing an additional 218,688 shares in the last quarter. Kentucky Trust Co bought a new position in shares of Zimmer Biomet during the fourth quarter valued at $39,000. Finally, Stonebridge Financial Group LLC bought a new position in shares of Zimmer Biomet during the fourth quarter valued at $25,000. 88.89% of the stock is owned by institutional investors.

Zimmer Biomet Stock Up 0.6 %

Shares of ZBH opened at $100.52 on Friday. The business’s 50 day moving average is $106.49 and its 200 day moving average is $107.79. The company has a market capitalization of $20.01 billion, a PE ratio of 22.59, a price-to-earnings-growth ratio of 1.83 and a beta of 1.02. Zimmer Biomet Holdings, Inc. has a 12-month low of $97.69 and a 12-month high of $133.90. The company has a current ratio of 1.91, a quick ratio of 0.70 and a debt-to-equity ratio of 0.43.

Zimmer Biomet (NYSE:ZBH) last issued its earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same quarter in the prior year, the firm posted $2.20 EPS. Research analysts expect that Zimmer Biomet Holdings, Inc. will post 8.25 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, January 31st. Shareholders of record on Monday, December 30th were paid a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a yield of 0.96%. The ex-dividend date was Monday, December 30th. Zimmer Biomet’s payout ratio is 21.57%.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on ZBH. Barclays lowered their price target on Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating on the stock in a report on Monday, February 10th. Royal Bank of Canada lowered their target price on Zimmer Biomet from $130.00 to $125.00 and set an “outperform” rating on the stock in a report on Friday, February 7th. JPMorgan Chase & Co. raised Zimmer Biomet from a “neutral” rating to an “overweight” rating and increased their target price for the company from $125.00 to $128.00 in a report on Tuesday, December 17th. Stifel Nicolaus increased their target price on Zimmer Biomet from $130.00 to $138.00 and gave the company a “buy” rating in a report on Thursday, January 23rd. Finally, Truist Financial reissued a “hold” rating and issued a $113.00 target price (down previously from $118.00) on shares of Zimmer Biomet in a report on Monday, February 10th. Two analysts have rated the stock with a sell rating, eleven have assigned a hold rating and ten have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $124.15.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.